Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis
Standard
Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. / Yanagisawa, Takafumi; Mori, Keiichiro; Katayama, Satoshi; Mostafaei, Hadi; Quhal, Fahad; Laukhtina, Ekaterina; Rajwa, Pawel; Motlagh, Reza S; Aydh, Abdulmajeed; König, Frederik; Grossmann, Nico C; Pradere, Benjamin; Miki, Jun; Schmidinger, Manuela; Egawa, Shin; Shariat, Shahrokh F.
In: IMMUNOTHERAPY-UK, Vol. 14, No. 9, 06.2022, p. 709-725.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis
AU - Yanagisawa, Takafumi
AU - Mori, Keiichiro
AU - Katayama, Satoshi
AU - Mostafaei, Hadi
AU - Quhal, Fahad
AU - Laukhtina, Ekaterina
AU - Rajwa, Pawel
AU - Motlagh, Reza S
AU - Aydh, Abdulmajeed
AU - König, Frederik
AU - Grossmann, Nico C
AU - Pradere, Benjamin
AU - Miki, Jun
AU - Schmidinger, Manuela
AU - Egawa, Shin
AU - Shariat, Shahrokh F
PY - 2022/6
Y1 - 2022/6
N2 - Aim: We aimed to assess the prognostic value of pretreatment hematological biomarkers in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). Methods: PubMed, Web of Science and Scopus databases were searched for articles according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Results: Fifteen studies comprising 1530 patients were eligible for meta-analysis. High levels of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein and lactate dehydrogenase were significantly associated with worse progression-free survival. High NLR and PLR were significantly associated with worse overall survival. Conclusion: High pretreatment NLR and PLR appear to be hematological prognostic factors of progression and overall mortality in mRCC patients treated with ICIs. These findings might help in the design of correlative biomarker studies to guide the clinical decision-making in the immune checkpoint inhibitor era.
AB - Aim: We aimed to assess the prognostic value of pretreatment hematological biomarkers in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). Methods: PubMed, Web of Science and Scopus databases were searched for articles according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Results: Fifteen studies comprising 1530 patients were eligible for meta-analysis. High levels of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein and lactate dehydrogenase were significantly associated with worse progression-free survival. High NLR and PLR were significantly associated with worse overall survival. Conclusion: High pretreatment NLR and PLR appear to be hematological prognostic factors of progression and overall mortality in mRCC patients treated with ICIs. These findings might help in the design of correlative biomarker studies to guide the clinical decision-making in the immune checkpoint inhibitor era.
KW - Biomarkers
KW - Carcinoma, Renal Cell/diagnosis
KW - Humans
KW - Immune Checkpoint Inhibitors/therapeutic use
KW - Kidney Neoplasms
KW - Lymphocytes/pathology
KW - Neutrophils/pathology
KW - Prognosis
U2 - 10.2217/imt-2021-0207
DO - 10.2217/imt-2021-0207
M3 - SCORING: Review article
C2 - 35465726
VL - 14
SP - 709
EP - 725
JO - IMMUNOTHERAPY-UK
JF - IMMUNOTHERAPY-UK
SN - 1750-743X
IS - 9
ER -
